SOHO Annual Meeting 2024
The Twelfth Annual Meeting of the Society of Hematologic Oncology, held from September 4-7, 2024, in Houston, Texas, focused the latest advances in treatment and management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms and related malignancies. The conference included general sessions, meet-the-professor sessions, plenary lectures, expert sessions, oral abstracts, and other interactive and informal exchanges.
The panel used an iterative process to create patient-facing and provider-facing consensus statements across 7 domains.
Researchers evaluated the renal status of more than 250 patients receiving TKIs in a chronic myeloid leukemia clinic.
Research presented at the Annual Meeting of the Society of Hematologic Oncology provided insights on outcomes and risks.
An analysis of the RESPONSE and RESPONSE-2 studies further supports the benefit of ruxolitinib in these patients.
Dr. Bose shared his insights at the Twelfth Annual Society of Hematologic Oncology Meeting in Houston.
A study of more than 10,000 patients illuminated the characteristics and needs of patients who are in remission.
Learn how an innovative rehabilitation model improved clinical outcomes and patient satisfaction with nursing care.
Learn about the diverse unmet needs and potential solutions related to the experiences of patients and caregivers.
Nurses, nurse administrators, physician assistants, and oncologists/hematologists shared their insights with researchers.
New research shows that major depressive disorder is associated with certain outcomes in this population of patients.
A new study highlights the importance of effective management and close monitoring of GVHD.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.